SEC Tracker
Get the app

Regeneron Pharmaceuticals REGN

Regeneron and Sanofi expand collaboration

Form
8-K
Filed
Importance
Routine
  1. $1.0 billion upfront payment from Sanofi to Regeneron
  2. Up to $7.0 billion in additional payments for milestones
  3. Co-development of four new antibodies targeting IL-13, IL-4, IL-4R, and IL-4xIL-13
  4. Global profits shared equally

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Regeneron Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zoetis ZTS public float $69.2B, Jun 30, 2025
  2. Idexx Laboratories IDXX public float $42.9B, Jun 30, 2025
  3. Alnylam Pharmaceuticals ALNY public float $42.6B, Jun 30, 2025
  4. Bristol Myers Squibb BMY public float $94.2B, Jun 30, 2025
  5. Gilead Sciences GILD public float $103.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.